Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 29

Sort by

Sort Order Select

Journal Articles

Machine learning–driven prognostication of overall survival at 6 months after CAR-T cell therapy

Blood (2025) 146 (Supplement 1): 2563.

https://doi.org/10.1182/blood-2025-2563

Published: 2025

Journal Articles

Incidence and risk factors for immune effector cell-associated neurotoxicity syndrome in older patients with relapsed or refractory large B-cell lymphoma: A multicenter study

Aung Tun, Romil Patel, Frederique St-Pierre, Evguenia Bhurtel, Alex Niu, Thorunn Thordardottir, Jennifer Obasi, Allison Rosenthal, Priyanka Pophali, Timothy Fenske, Reem Karmali, Patrick Johnston, Sairah Ahmed

Blood (2025) 146 (Supplement 1): 6310.

https://doi.org/10.1182/blood-2025-6310

Published: 2025

Journal Articles

Prognostic factors and therapeutic outcomes in neurolymphomatosis: A 22-year cohort study from Mayo Clinic

Ayo Falade, Abiola Bolarinwa, Oluwatayo Adeoye, Muhammad Yousuf, Allison Rosenthal, Mazie Tsang, Madiha Iqbal, Daniel Lachance, Rebecca King, Yucai Wang, Micallef Ivana, Robert Spinner, Thomas Habermann, Grzegorz Nowakowski, Arushi Khurana, Patrick Johnston

Blood (2025) 146 (Supplement 1): 6306.

https://doi.org/10.1182/blood-2025-6306

Published: 2025

Journal Articles

Real-world treatment patterns and survival outcomes in primary CNS lymphoma: Analysis of the national cancer database

Ayo Falade, Yu Tao, Olisaemeka Ogbue, Oluwatayo Adeoye, Ayodeji Johnson, Arushi Khurana, Jithma Abeykoon, Urshila Durani, Mazie Tsang, Allison Rosenthal, Talal Hilal, Javier Munoz, Patrick Johnston, Han Tun, Grzegorz Nowakowski, James Cerhan, Richard Godby, Yucai Wang, Jihao Zhou

Blood (2025) 146 (Supplement 1): 4494.

https://doi.org/10.1182/blood-2025-4494

Published: 2025

Journal Articles

Prognostic significance of cell-of-origin, gene expression profiles, and frontline therapy in predicting secondary CNS lymphoma in newly diagnosed diffuse large B-cell lymphoma

Blood (2025) 146 (Supplement 1): 473.

https://doi.org/10.1182/blood-2025-473

Published: 2025

Journal Articles

Anatomical localization-based analysis of de novo secondary cns lymphoma

Izel Okcu, Zhuo Li, Launia White, Yucai Wang, Patrick Johnston, Allison Rosenthal, Arushi Khurana, Urshila Durani, Jonas Paludo, Rebecca King, Thomas Witzig, Thomas Habermann, Grzegorz Nowakowski, Han Tun

Blood (2025) 146 (Supplement 1): 3675.

https://doi.org/10.1182/blood-2025-3675

Published: 2025

Journal Articles

Lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) for second-line relapsed or refractory large B-cell lymphoma (LBCL): First Results from long-term follow-up of TRANSFORM

Manali Kamdar, Scott Solomon, Jon Arnason, Patrick Johnston, Bertram Glass, Veronika Bachanova, Sami Ibrahimi, Stephan Mielke, Pim Mutsaers, Francisco Hernandez-Ilizaliturri, Koji Izutsu, Franck Morschhauser, Matthew Lunning, Vincent Ribrag, Yi Lin, Rashmi Bhatnagar, Sandrine Montheard, Jeremy Abramson

Blood (2025) 146 (Supplement 1): 3710.

https://doi.org/10.1182/blood-2025-3710

Published: 2025

Journal Articles

AI multimodal large language model on CAR-T pre-leukapheresis evaluation to predict monitoring needs post infusion for early dismissal planning

Blood (2025) 146 (Supplement 1): 6131.

https://doi.org/10.1182/blood-2025-6131

Published: 2025

Journal Articles

Metabolic pathway signatures unpinning response to CD19 CAR T-cell therapy in aggressive B-cell non-Hodgkin's lymphoma

Blood (2025) 146 (Supplement 1): 5894.

https://doi.org/10.1182/blood-2025-5894

Published: 2025

Journal Articles

Large language model for abstraction of CAR-T therapy toxicities data

Blood (2025) 146 (Supplement 1): 6139.

https://doi.org/10.1182/blood-2025-6139

Published: 2025

Journal Articles

Tumor-derived microRNA-125a impairs CART cell function and predicts treatment failure in B cell malignancies

Blood (2025) 146 (Supplement 1): 2321.

https://doi.org/10.1182/blood-2025-2321

Published: 2025

Journal Articles

Baseline Hypoalbuminemia Does Not Appear to be an Adverse Prognostic Factor in Patients with Relapse/Refractory B-Cell Lymphomas Treated with Axicabtagene Ciloleucel (axi-cel)

Blood (2019) 134 (Supplement_1): 5343.

https://doi.org/10.1182/blood-2019-126594

Published: 2019

Journal Articles

Event-Free Survival at 24 Months Following Autologous Stem Cell Transplant in Diffuse Large B-Cell Lymphoma

Seth M Maliske, MD, Matthew J. Maurer, MS, Carrie A. Thompson, MD, Luis Porrata, MD, Ivana Micallef, MD, Rebecca L. King, MD, Sergei Syrbu, MD PhD, Brian K. Link, MD, Margarida Magalhaes Silverman, MD, Yogesh Jethava, MBBS,MDFRCPath,MRCP, David James J Inwards, MD, Stephen M Ansell, MD PhD, James R. Cerhan, MD PhD, Patrick Johnston, MD PhD, Umar Farooq, MD

Blood (2019) 134 (Supplement_1): 2896.

https://doi.org/10.1182/blood-2019-124579

Published: 2019

Journal Articles

Central Nervous System Involvement in Peripheral T-Cell Lymphoma

Sangeetha Gandhi, MBBS, N. Nora Bennani, MD, Sonia Fortin, Thomas M. Habermann, MD, Patrick Johnston, MD, James R. Cerhan, MD PhD, Kay M. Ristow, BS, Carrie A. Thompson, MD, Grzegorz Nowakowski, MD, Yi Lin, MD PhD, Jose C Villasboas, MD, Luis Porrata, MD, Thomas E. Witzig, MD, Ivana Micallef, MD, David J Inwards, MD, Stephen M Ansell, MD PhD, Jonas Paludo, MD

Blood (2019) 134 (Supplement_1): 5293.

https://doi.org/10.1182/blood-2019-131965

Published: 2019

Journal Articles

Clinical Features and Treatment for Neurolymphomatosis in the Rituximab Era: Single Institution Experience

Mattia Novo, Grzegorz Nowakowski, MD, Ivana Micallef, MD, Rebecca L. King, MD, Robert Spinner, MD, Kay M. Ristow, BS, Thomas M. Habermann, MD, Patrick Johnston, MD PhD

Blood (2019) 134 (Supplement_1): 4129.

https://doi.org/10.1182/blood-2019-131378

Published: 2019

Journal Articles

Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene Ciloleucel Therapy for Lymphoma

Blood (2019) 134 (Supplement_1): 4106.

https://doi.org/10.1182/blood-2019-127094

Published: 2019

Journal Articles

Short Time between Progression after Immunochemotherapy and Initiation of Salvage Therapy (PTI) Is Associated with Inferior Long-Term Outcomes in Patients with Relapsed/Refractory DLBCL

Matthew J. Maurer, MS, Umar Farooq, MD, Madison M Wahlen, Thomas M. Habermann, MD, Gita Thanarajasingam, MD, Sergei Syrbu, MD PhD, William R. Macon, MD, Patrick Johnston, MD, Ivana Micallef, MD, Luis Porrata, MD, Susan L. Slager, PhD, Stephen M. Ansell, MD PhD, Thomas E. Witzig, MD, James R. Cerhan, MD PhD, Grzegorz S. Nowakowski, MD, Carrie A. Thompson, MD, Brian K. Link, MD

Blood (2018) 132 (Supplement 1): 4204.

https://doi.org/10.1182/blood-2018-99-114331

Published: 2018

Journal Articles

Non-Diffuse Large B-Cell Primary Central Nervous System Lymphoma

Sangeetha Gandhi, MBBS, Grzegorz S. Nowakowski, MD, Thomas M. Habermann, MD, Kay M. Ristow, BS, Patrick Johnston

Blood (2018) 132 (Supplement 1): 4208.

https://doi.org/10.1182/blood-2018-99-119741

Published: 2018

Journal Articles

Role of Systemic High-Dose Methotrexate and Combined Approaches in the Management of Vitreoretinal Diffuse Large B-Cell Lymphoma: A Single Center Experience 1990-2018

Alessia Castellino, MD, Jose Pulido, PhD, Patrick Johnston, Kay M. Ristow, BS, Nabila Nora Bennani, MD, David J Inwards, MD, William R. Macon, MD, Ivana N Micallef, MD, Rebecca L King, MD, Diva Salomao, MD, Thomas E. Witzig, MD, Thomas M. Habermann, MD, Grzegorz Nowakowski, MD

Blood (2018) 132 (Supplement 1): 574.

https://doi.org/10.1182/blood-2018-99-113826

Published: 2018

Journal Articles

Impact of MYD88 L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia

Blood (2018) 132 (Supplement 1): 2884.

https://doi.org/10.1182/blood-2018-99-120046

Published: 2018

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Machine learning–driven prognostication of overall survival at 6 months after CAR-T cell therapy

Incidence and risk factors for immune effector cell-associated neurotoxicity syndrome in older patients with relapsed or refractory large B-cell lymphoma: A multicenter study

Prognostic factors and therapeutic outcomes in neurolymphomatosis: A 22-year cohort study from Mayo Clinic

Real-world treatment patterns and survival outcomes in primary CNS lymphoma: Analysis of the national cancer database

Prognostic significance of cell-of-origin, gene expression profiles, and frontline therapy in predicting secondary CNS lymphoma in newly diagnosed diffuse large B-cell lymphoma

Anatomical localization-based analysis of de novo secondary cns lymphoma

Lisocabtagene maraleucel (liso-cel) versus standard of care (SOC) for second-line relapsed or refractory large B-cell lymphoma (LBCL): First Results from long-term follow-up of TRANSFORM

AI multimodal large language model on CAR-T pre-leukapheresis evaluation to predict monitoring needs post infusion for early dismissal planning

Metabolic pathway signatures unpinning response to CD19 CAR T-cell therapy in aggressive B-cell non-Hodgkin's lymphoma

Large language model for abstraction of CAR-T therapy toxicities data

Tumor-derived microRNA-125a impairs CART cell function and predicts treatment failure in B cell malignancies

Baseline Hypoalbuminemia Does Not Appear to be an Adverse Prognostic Factor in Patients with Relapse/Refractory B-Cell Lymphomas Treated with Axicabtagene Ciloleucel (axi-cel)

Event-Free Survival at 24 Months Following Autologous Stem Cell Transplant in Diffuse Large B-Cell Lymphoma

Central Nervous System Involvement in Peripheral T-Cell Lymphoma

Clinical Features and Treatment for Neurolymphomatosis in the Rituximab Era: Single Institution Experience

Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene Ciloleucel Therapy for Lymphoma

Short Time between Progression after Immunochemotherapy and Initiation of Salvage Therapy (PTI) Is Associated with Inferior Long-Term Outcomes in Patients with Relapsed/Refractory DLBCL

Non-Diffuse Large B-Cell Primary Central Nervous System Lymphoma

Role of Systemic High-Dose Methotrexate and Combined Approaches in the Management of Vitreoretinal Diffuse Large B-Cell Lymphoma: A Single Center Experience 1990-2018

Impact of MYD88 L265P mutation Status on Histological Transformation of Waldenstrom Macroglobulinemia

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only